Moderna says updated next-generation COVID shot shows strong immune response in patients

Moderna announced its updated COVID-19 vaccine, mNEXSPIKE, for the 2025-2026 season, demonstrated a strong immune response in adults aged 65+ and at-risk individuals, showing over a 16-fold increase in neutralizing antibodies against the prevalent LP.8.1 variant with a consistent safety profile. This preliminary positive data is significant for Moderna, which is relying on newer mRNA vaccines to counter waning demand for its original Spikevax and disappointing RSV vaccine uptake, especially given mNEXSPIKE's FDA approval in May under more stringent regulatory requirements.

Analysis

Moderna (MRNA) has reported positive preliminary data for its updated 2025-2026 COVID-19 vaccine, mNEXSPIKE, which showed a greater than 16-fold increase in neutralizing antibodies against the LP.8.1 variant in adults over 65 and other at-risk individuals. This clinical milestone is strategically significant as the company faces waning demand for its original Spikevax shot and disappointing uptake of its RSV vaccine. The strong immunogenicity data, coupled with a consistent safety profile, provides crucial validation for Moderna's next-generation mRNA platform under the FDA's more stringent approval requirements established in May. This development directly supports the company's core strategy of transitioning its COVID-19 product line into a sustainable, seasonal revenue stream, a key factor for its long-term valuation now that pandemic-level demand has subsided.

Key Decisions for Investors

• Investors may view this positive preliminary data as a key de-risking event for Moderna's future revenue pipeline, reinforcing the bull case for its ability to establish a durable seasonal vaccine franchise.
• It is now critical to monitor for final study data, global regulatory filings, and management's commentary on market access and pricing to quantify the potential commercial success of mNEXSPIKE.
• Consider this positive development in the context of the company's broader commercial execution, as the success of this new vaccine must be sufficient to offset the documented revenue headwinds from its legacy Spikevax and new RSV products.